Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of NX-1607 in Adults With Advanced Malignancies
Complete Title: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Trial Phase: I
Investigator: John Liao
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Keywords:
- Gastric Cancer
- Head and Neck Cancer
- Melanoma
- Mesothelioma
- Ovarian Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Prostate Cancer, Castration-resistant (CRPC)
- Colorectal Neoplasms
- Lymphoma, Large B-Cell, Diffuse
- Triple Negative Breast Neoplasms
- Urothelial Cancer
- Gastroesophageal Junction Cancer
- Richter Syndrome
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
John Liao
RG1123233
NCT05107674
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types
Gastric Cancer
Head and Neck Cancer
Melanoma
Mesothelioma
Ovarian Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Prostate Cancer, Castration-resistant (CRPC)
Colorectal Neoplasms
Lymphoma, Large B-Cell, Diffuse
Triple Negative Breast Neoplasms
Urothelial Cancer
Gastroesophageal Junction Cancer
Richter Syndrome